Journal of Clinical Oncology, Vol 10, 459-463, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma

ER Ellis, RB Marcus Jr, MJ Cicale, DS Springfield, FJ Bova, J Graham-Pole, WF Enneking, SS Spanier and RR Million
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville 32610-0385.

PURPOSE: Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma. PATIENTS AND METHODS: Between 1979 and 1984, 57 osteogenic sarcoma patients with no evidence of metastatic disease at diagnosis received adjuvant therapy consisting of whole-lung irradiation (with the heart shielded) followed by Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). The whole-lung irradiation schema was 1,600 cGy in 10 fractions with 8-MV x- rays via anterior and posterior fields. This was followed by five cycles of Adriamycin for a total dose of 450 mg/m2. Pulmonary function tests (PFTs) consisting of spirometry, lung volumes, and diffusing capacity were obtained before the whole-lung irradiation, at 6 and 12 months after irradiation, and at yearly intervals thereafter. RESULTS: At the time of analysis, 28 of the 57 patients were available for study, with a mean follow-up of 42 months (range, 6 to 77 months). Follow-up pulmonary function testing revealed decreased forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1) during the first 6 to 12 months after whole-lung irradiation. These values returned to baseline during the second-year posttherapy and remained at baseline throughout the remainder of the follow-up period. Changes in lung volumes demonstrated a similar early trend, with significant decreases in total lung capacity (TLC) and functional residual capacity (FRC) at 6 to 12 months. These changes, however, did not improve significantly during the remainder of the follow-up period. Diffusing capacity of the lungs for carbon monoxide (DLCO) also reached a nadir at 6 to 12 months after whole-lung irradiation, with resolution by 2 years and maintenance of at least baseline values for the remainder of the follow-up period. CONCLUSIONS: Treatment with whole-lung irradiation and Adriamycin, as given in this study, caused no significant sequelae, as demonstrated by pulmonary function testing during the mean follow-up period of 42 months, although a mild, transient restrictive ventilatory defect occurred at 6 to 12 months after treatment.

This article has been cited by other articles:

				J. S. Whelan, R. J. Burcombe, J. Janinis, A. M. Baldelli, and A. M. Cassoni A systematic review of the role of pulmonary irradiation in the management of primary bone tumours Ann. Onc., January 19, 2002; 13(1): 23 - 30. [Abstract] [Full Text] [PDF]

				R. B. Mosher and B. J. McCarthy Late Effects in Survivors of Bone Tumors Late Effects in Survivors of Bone Tumors Journal of Pediatric Oncology Nursing, January 1, 1998; 15(2): 72 - 84. [Abstract] [PDF]